GTAEXS617
GTAEXS617-001
Phase 2 small_molecule active
Quick answer
GTAEXS617 for Head and Neck Squamous Cell Carcinoma (HNSCC) is a Phase 2 program (small_molecule) at RECURSION PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RECURSION PHARMACEUTICALS, INC.
- Indication
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active